Clinical Trials Directory

Trials / Terminated

TerminatedNCT03485313

Beta-hCG Test Reference Range Determination

Clinical Evaluation to Determine the Expected Values Distribution of β-hCG for the RAMP® Total β-hCG Test in a Healthy, Non-pregnant Reference Population

Status
Terminated
Phase
Study type
Observational
Enrollment
137 (actual)
Sponsor
Response Biomedical Corp. · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

Prospective, single-centre study to determine the reference range (95th percentile) of human chorionic gonadotropin (hCG) levels in a healthy, non-pregnant, adult female population using the RAMP® Total β-hCG test.

Detailed description

Human chorionic gonadotropin (hCG) is a glycoprotein hormone secreted by the placenta shortly after implantation of a fertilized ovum into the uterine wall and the rapid rise of blood hCG concentration after conception makes it an excellent marker for confirmation and monitoring of early pregnancy. As such, levels in the blood of non-pregnant premenopausal individuals are low, typically \< 5 mIU/mL (milli-International Unit per milliliter). In terms of identifying a clinically significant range of expected hCG values as determined by the RAMP β-hCG test, a 95th percentile of a healthy, non-pregnant, adult female reference population \[upper reference limit (URL)\] shall be determined in this study. Subjects who meet the inclusion and exclusion criteria, and give informed consent will be enrolled in this study. Because hCG levels in blood increase with age, the study population will be divided into two age groups: 18 to 40 years and \>40 years, with approximately 125 subjects per group. One EDTA (ethylenediaminetetraacetic acid) blood sample will be collected from each subject via standard venipuncture. The maximum trial duration for each subject will be one visit/blood draw.

Conditions

Timeline

Start date
2018-04-25
Primary completion
2018-07-18
Completion
2018-08-29
First posted
2018-04-02
Last updated
2019-01-25

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03485313. Inclusion in this directory is not an endorsement.